Previous 10 | Next 10 |
home / stock / trypf / trypf news
Tryp Therapeutics Appoints New Chief Operating Officer Canada NewsWire Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments SAN ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced the results gathered from the first patient dosed in its phase II STOP clinical trial. According to the...
TRYP THERAPEUTICS ANNOUNCES RESULTS OF FIRST PATIENT DOSED IN ITS PHASE II CLINICAL TRIAL FOR THE TREATMENT OF BINGE EATING DISORDER Canada NewsWire Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatme...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive e...
Tryp Therapeutics Strengthens Board of Directors with Appointment of Chris Ntoumenopoulos as Independent Director Canada NewsWire Industry leader Chris Ntoumenopoulos to support biotech Company's mission to advance the delivery of psychedelic medicines SAN DIEG...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the first patient has been dosed in the company’s phase II clinical trial for its lead ca...
TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL Canada NewsWire Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder SAN DIEGO , ...
(TheNewswire) SAN DIEGO, CALIFORNIA – TheNewswire - April 22, 2022 – Tryp Therapeutics (CSE:TRYP) (OTC:TRYPF) (“ Tryp ” or the “ Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the first patient enrolled to evaluate its clinical candidate, TRP-8802, in a clinical trial. The study will be con...
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida Canada NewsWire Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics Inc Com Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...